On this page
POU1F1
POU class 1 homeobox 1
POU1F1 is located on the short (p) arm of chromosome 3, at band 3p11.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 3 in the library →Available at Jeen Health
Clinical tests that include this
Overview
POU1F1 is located on chromosome 3 and encodes a member of the POU family of transcription factors. This protein plays a critical regulatory role during embryonic development and throughout life by controlling the activity of genes required for the proper function of the anterior pituitary gland. The anterior pituitary produces several hormones that regulate growth, metabolism, stress response, and reproduction. When POU1F1 is disrupted by pathogenic variants, individuals may experience deficiencies in growth hormone, thyroid-stimulating hormone, and prolactin. This gene is particularly important in endocrinology, as variants can present in infancy with features such as growth failure and hypothyroidism. Understanding POU1F1 function helps clinicians recognise and manage pituitary hormone deficiencies in affected individuals.
What the gene does
The POU1F1 protein acts as a transcription factor, meaning it binds to specific DNA sequences and regulates whether nearby genes are switched on or off. During embryonic development, POU1F1 is essential for the differentiation and survival of somatotrophs (growth hormone-producing cells), lactotrophs (prolactin-producing cells), and thyrotrophs (thyroid-stimulating hormone-producing cells) within the anterior pituitary. The protein achieves this regulatory function by recognising and binding to target gene promoters, thereby activating transcription of genes such as growth hormone and thyroid-stimulating hormone beta subunit. Beyond development, POU1F1 continues to maintain the expression of these hormones in adult life. The protein's ability to coordinate the expression of multiple pituitary hormones means that disruption of POU1F1 typically results in combined hormone deficiencies rather than isolated defects. This transcriptional control is critical for normal postnatal growth, metabolic homeostasis, and lactation.
Video: Genetics 101
Chromosome location
POU1F1 is located on the short arm of chromosome 3 at position p11.2 (3p11.2). The genomic sequence comprises multiple exons that together encode the mature messenger RNA transcript. The chromosomal band 3p11.2 is a region containing several genes involved in developmental processes, though POU1F1 is the primary gene in this locus associated with pituitary hormone deficiency.
Protein structure
The POU1F1 protein is 291 amino acids in length and contains several functionally important regions. Near the N-terminus, a 9aaTAD motif spans amino acids 5-13 and contributes to transcriptional activation. The central portion of the protein contains the POU-specific domain, extending from amino acids 124-198, which is characteristic of the POU family and participates in DNA recognition and protein-protein interactions. Towards the C-terminus, a homeobox domain (amino acids 214-273) provides DNA-binding capability, allowing the protein to recognise specific nucleotide sequences in target gene promoters. Together, the POU-specific and homeobox domains form the functional POU domain, a bipartite DNA-binding structure that enables selective gene regulation in pituitary cells.
Key variants
Pathogenic variants in POU1F1 have been identified throughout the gene, affecting different functional domains. These variants include missense changes that disrupt DNA binding or protein stability, nonsense variants that truncate the protein, and small deletions or insertions that alter the reading frame. The impact of a variant often depends on which domain is affected and whether it abolishes protein function entirely or reduces activity. Both autosomal recessive and autosomal dominant inheritance patterns have been reported, with some dominant variants exerting dominant-negative effects by interfering with wild-type protein function. Genetic testing can identify pathogenic variants in individuals presenting with combined pituitary hormone deficiency.
No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.
Associated conditions
Variants in POU1F1 are primarily associated with combined pituitary hormone deficiency, a condition characterised by insufficient production of growth hormone, thyroid-stimulating hormone, and prolactin. Affected individuals typically present in early childhood with short stature, delayed growth milestones, and features of congenital hypothyroidism such as prolonged jaundice, feeding difficulties, and developmental delay. The severity and specific hormone deficiencies can vary depending on the nature of the genetic variant. Some individuals may have isolated growth hormone deficiency initially, with additional hormone deficits becoming apparent over time. Early recognition and hormone replacement therapy can significantly improve outcomes for affected children.
No disease links recorded for this gene in our reference set.
UK clinical status
POU1F1 is included on several NHS Genomic Medicine Service panels, reflecting its clinical significance in paediatric endocrinology. The gene appears on the Pituitary hormone deficiency panel (R159), Congenital hypothyroidism panel (R145), and Fetal anomalies panel (R21) with green (diagnostic-grade) classification, indicating strong evidence for its role in these conditions. It is also listed on the IUGR and IGF abnormalities panel and the Developmental Disorders Genotype-to-Phenotype (DDG2P) database. These panel inclusions support the use of POU1F1 sequencing in the diagnostic evaluation of children with unexplained growth failure, congenital hypothyroidism, or other features suggestive of combined pituitary hormone deficiency.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What symptoms might suggest a POU1F1 variant?
Individuals with pathogenic POU1F1 variants may present with short stature, delayed growth, features of hypothyroidism (such as prolonged neonatal jaundice or low energy), and in some cases delayed puberty. Early diagnosis through genetic testing enables timely hormone replacement therapy.
How is combined pituitary hormone deficiency managed?
Management typically involves lifelong hormone replacement therapy tailored to the specific deficiencies, which may include growth hormone, levothyroxine for thyroid function, and in some cases sex hormones or cortisol. Regular monitoring by a paediatric or adult endocrinologist is essential.
Can POU1F1 variants be inherited?
Yes, POU1F1 variants can be inherited in either an autosomal recessive or autosomal dominant pattern depending on the specific variant. Genetic counselling can help families understand recurrence risks and inheritance patterns.